SEC Form 6-K filed by SOPHiA GENETICS SA
$SOPH
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2025.
____________________________________
Commission File Number: 001-40627
SOPHiA GENETICS SA
(Exact name of registrant as specified in its charter)
La Pièce 12
CH-1180 Rolle
Switzerland
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
| Form 20-F | x | Form 40-F | |||||||||||||||
SIGNATURE
SOPHiA GENETICS SA (the “Company”) today published its Environmental, Social and Governance Impact Summary as per December 31, 2024 (“2024 ESG Impact Summary”). The 2024 ESG Impact Summary is available on www.sophiagenetics.com, in the Investor Relations section.
| SOPHiA GENETICS SA | |||||||||||
| Date: | May 16, 2025 | ||||||||||
| By: | /s/ Daan van Well | ||||||||||
| Name: | Daan van Well | ||||||||||
| Title: | Chief Legal and Regulatory Officer | ||||||||||
EXHIBIT INDEX
| Exhibit No. | Description | ||||